Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scan could replace dye injections for diabetic retinopathy

NCT ID NCT02330042

Knowledge-focused Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether a special type of eye scan called functional OCT can detect early blood vessel damage in people with diabetic retinopathy. Currently, doctors use a dye injection to see these changes, which can cause side effects. The study will enroll 165 people with diabetes to see if the scan can spot reduced blood flow, abnormal blood vessels, and swelling in the retina without needing a dye.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a safer, dye-free way to monitor diabetic retinopathy and catch vision-threatening changes earlier.
What could go wrong
This is an observational study, not a treatment trial. The new scan may not prove reliable enough to replace current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

165 people

The number who actually took part.

Started

Jan 2015

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with Type 1 diabetes of greater than 5 years duration OR Type 2 diabetes of any duration. Healthy controls are also being enrolled in this study.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for participants with diabetes: * Male or female participants 18-79 years old * With Type 1 diabetes for over 5 years or Type 2 diabetes of any duration Exclusion Criteria for participants with diabetes: * Vision worse than 20/200 * Inability to maintain fixation for OCT imaging * Significant kidney disease, kidney failure or kidney transplant * Unstable medical status, including blood pressure greater than 180/110 or unstable heart disease * Pregnant or nursing an infant * Presence of an eye disease (other than diabetic retinopathy) that can affect retinal blood flow, retinal permeability or retinal anatomy * Significant cataract, corneal scar, vitreous bleed or other media opacity * History of major eye surgery within 4 months prior to enrollment in this study Inclusion Criteria for participants without diabetes (controls): * Male or female participants 18-79 years old Exclusion Criteria for participants without diabetes (controls): * Vision worse than 20/200 * Inability to maintain fixation for OCT imaging * Significant kidney disease, kidney failure or kidney transplant * Unstable medical status, including blood pressure greater than 180/110 or unstable heart disease * Pregnant or nursing an infant * Presence of any eye disease that can affect retinal blood flow, retinal permeability or retinal anatomy * Significant cataract, corneal scar, vitreous bleed or other media opacity * History of major eye surgery within 4 months prior to enrollment in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic retinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic retinopathy

Contacts and locations

Locations

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.